Targeting Lipid Metabolism in Cancer Stem Cells for Anticancer Treatment
Open Access
- 17 October 2024
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (20) , 11185
Abstract
Cancer stem cells (CSCs), or tumor-initiating cells (TICs), are small subpopulations (0.0001–0.1%) of cancer cells that are crucial for cancer relapse and therapy resistance. The elimination of each CSC is essential for achieving long-term remission. Metabolic reprogramming, particularly lipids, has a significant impact on drug efficacy by influencing drug diffusion, altering membrane permeability, modifying mitochondrial function, and adjusting the lipid composition within CSCs. These changes contribute to the development of chemoresistance in various cancers. The intricate relationship between lipid metabolism and drug resistance in CSCs is an emerging area of research, as different lipid species play essential roles in multiple stages of autophagy. However, the link between autophagy and lipid metabolism in the context of CSC regulation remains unclear. Understanding the interplay between autophagy and lipid reprogramming in CSCs could lead to the development of new approaches for enhancing therapies and reducing tumorigenicity in these cells. In this review, we explore the latest findings on lipid metabolism in CSCs, including the role of key regulatory enzymes, inhibitors, and the contribution of autophagy in maintaining lipid homeostasis. These recent findings may provide critical insights for identifying novel pharmacological targets for effective anticancer treatment.Keywords
Funding Information
- National Research Foundation of Korea (NRF-2018R1A6A1A03025124)
This publication has 246 references indexed in Scilit:
- Cancer cells employ lipid droplets to survive toxic stressThe Prostate, 2024
- Aldehyde dehydrogenase in solid tumors and other diseases: Potential biomarkers and therapeutic targetsMedcomm, 2023
- 4‐phenylbutyric acid promotes hepatocellular carcinoma via initiating cancer stem cells through activation of PPAR‐αClinical and Translational Medicine, 2021
- Autophagy, cancer stem cells and drug resistanceThe Journal of Pathology, 2018
- PD‐L1 promotes OCT4 and Nanog expression in breast cancer stem cells by sustaining PI3K/AKT pathway activationInternational Journal of Cancer, 2017
- Lipid Droplets: A New Player in Colorectal Cancer Stem Cells Unveiled by Spectroscopic ImagingStem Cells, 2014
- Exogenous fatty acid binding protein 4 promotes human prostate cancer cell progressionInternational Journal of Cancer, 2014
- Cancer Stem Cell-Specific Scavenger Receptor CD36 Drives Glioblastoma ProgressionStem Cells, 2014
- FoxO3a Functions as a Key Integrator of Cellular Signals That Control Glioblastoma Stem-like Cell Differentiation and TumorigenicityStem Cells, 2011
- Aberrations in Normal Systemic Lipid Metabolism in Ovarian Cancer PatientsGynecologic Oncology, 1996